ScholarIQanswers from OpenAlex
National Cancer Center
InstitutionResearch output, impact & collaborations
National Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about National Cancer Center?
ScholarIQrecord summary
National Cancer Center is a research organisation in Plainview, US. OpenAlex records 16,759 works and 1,378,293 citations for it. 5,427 researchers list it as their most recent affiliation.
How many works does National Cancer Center have?
ScholarIQindexed works
National Cancer Center has 16,759 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does National Cancer Center have?
ScholarIQcitation count
National Cancer Center has 1,378,293 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at National Cancer Center?
ScholarIQresearcher count
National Cancer Center has 5,427 researchers in the ScholarIQ index.
What is the average h-index at National Cancer Center?
ScholarIQavg h-index
National Cancer Center has an average h-index of 66.4 in OpenAlex.
What is the ROR of National Cancer Center?
ScholarIQror
The ROR for National Cancer Center is on the source record.
What is the OpenAlex record for National Cancer Center?
ScholarIQopenalex
The OpenAlex for National Cancer Center is on the source record.
Who are the most-cited researchers behind National Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on National Cancer Center?
ScholarIQmost cited works
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
Hisashi Saji, Morihito Okada, Masahiro Tsuboi, Ryu Nakajima, Kenji Suzuki, Keiju Aokage, Tadashi Aoki, Jiro Okami, Ichiro Yoshino, Hiroyuki Ito, Norihito Okumura, Masafumi Yamaguchi, Norihiko Ikeda, Masashi Wakabayashi, Kenichi Nakamura, Haruhiko Fukuda, Shinichiro Nakamura, Tetsuya Mitsudomi, Shun‐ichi Watanabe, Hisao Asamura
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
Shinichi Yachida, Sayaka Mizutani, Hirotsugu Shiroma, Satoshi Shiba, Takeshi Nakajima, Taku Sakamoto, Hikaru Watanabe, Keigo Masuda, Yuichiro Nishimoto, Masaru Kubo, Fumie Hosoda, Hirofumi Rokutan, Minori Matsumoto, Hiroyuki Takamaru, Masayoshi Yamada, Takahisa Matsuda, Motoki Iwasaki, Taiki Yamaji, Tatsuo Yachida, Tomoyoshi Soga, Ken Kurokawa, Atsushi Toyoda, Yoshitoshi Ogura, Tetsuya Hayashi, Masanori Hatakeyama, Hitoshi Nakagama, Yutaka Saito, Shinji Fukuda, Tatsuhiro Shibata, Takuji Yamada
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chìn, Shigenori Kadowaki, Myung‐Ju Ahn, Yasuo Hamamoto, Yuichiro� Doki, Chueh‐Chuan Yen, Yutaro Kubota, Sung‐Bae Kim, Chih‐Hung Hsu, Eva Holtved, Ioannis Xynos, Mamoru Kodani, Yuko Kitagawa
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
How much of the research on National Cancer Center is open access?
ScholarIQopen access share
75%OPEN ACCESS